LCZ696 is a heart failure drug from Novartis that many observers think will gain FDA approval later this year and go on to become a blockbuster. Perhaps the biggest obstacle to the drug’s success is the fear that it might raise the risk of Alzheimer’s disease. Now a new article in a top cardiology journal lays out the detailed basis for…
New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer’s Disease?
February 9, 2015 by Leave a Comment
No Evidence That Statins Impact Cognitive Function
November 18, 2013 by Leave a Comment
In 2012 the FDA revised the label of statins to include a warning about reports that the drugs had been linked to memory loss or confusion. The FDA action appeared to be based largely on case reports. Despite concerns about this topic that have appeared sporadically in recent years, no high-quality review of the topic has appeared until now….
Possible Cognitive Benefits Found In Dementia Patients Taking Centrally Acting ACE Inhibitors
July 25, 2013 by Leave a Comment
An observational study from Ireland raises the intriguing possibility that certain blood pressure lowering drugs, centrally acting ACE inhibitors, may help slow the cognitive decline that is a hallmark of people with Alzheimer’s disease and other forms of dementia. The study, published in BMJ Open, followed the rates of cognitive decline in 3 groups of patients: dementia patients being treated…
Recent Comments